Proscar Related Published Studies
Well-designed clinical trials related to Proscar (Finasteride)
Change in sexual function in men with lower urinary tract symptoms/benign
prostatic hyperplasia associated with long-term treatment with doxazosin,
finasteride and combined therapy. [2014]
Long-term effects of doxazosin, finasteride, and combination therapy on quality
of life in men with benign prostatic hyperplasia. [2013]
Long-term effects of doxazosin, finasteride and combination therapy on quality of
life in men with benign prostatic hyperplasia. [2013]
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide
vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. [2013]
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). [2011.08]
Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. [2011.04]
Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics. [2011.03]
Comparative effect of finasteride and dutasteride on chromogranin A levels. [2010.11]
Finasteride for benign prostatic hyperplasia. [2010.10.06]
Effect of finasteride on ovulation induction in nonresponder (hyperandrogenic) polycystic ovary syndrome (PCOS) women. [2010.06]
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. [2010.03]
Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study. [2009.10]
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. [2009.05]
Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. [2009.02]
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. [2008.09]
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. [2008.08]
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. [2008.08]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. [2008.06]
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. [2007.09.19]
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. [2007.09.19]
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. [2007.07.20]
Finasteride decreases the risk of prostatic intraepithelial neoplasia. [2007.07]
Finasteride Decreases the Risk of Prostatic Intraepithelial Neoplasia. [2007.05.10]
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. [2007.05]
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. [2007.05]
The Effect of 5{alpha}-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men. [2007.02.13]
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. [2006.12]
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. [2006.08.16]
Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. [2006.08]
Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. [2006.07]
Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. [2005.12]
[Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia] [2005.12]
Effects of finasteride (1 mg) on hair transplant. [2005.10]
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. [2005.09]
GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. [2005.06]
The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. [2005.03]
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. [2005.03]
Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). [2005.01]
An 18-month follow-up study after randomized treatment of phimosis in boys with topical steroid versus placebo. [2005]
Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. [2005]
Bioequivalence study of two different coated tablet formulations of finasteride in healthy volunteers. [2005]
Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. [2004.10]
Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. [2004.09]
Finasteride in the treatment of Japanese men with male pattern hair loss. [2004.07]
[Effect of finasteride on intraoperative bleeding and irrigating fluid absorption during transurethral resection of prostate: a quantitative study] [2004.05]
A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). [2004.05]
A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. [2004.03]
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. [2004.03]
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. [2004.02]
A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. [2004.01]
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. [2004]
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. [2003.12.18]
Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. [2003.11]
The influence of finasteride on the development of prostate cancer. [2003.07.17]
[Determination of finasteride in human plasma by HPLC-MS] [2003.06]
Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. [2003.04]
Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. [2003.04]
Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. [2003.03]
Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. [2003.03]
The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism. [2003.02]
Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. [2003.02]
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. [2003.01]
A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. [2003]
Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. [2002.11]
Changes in molecular forms of prostate-specific antigen during treatment with finasteride. [2002.11]
Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. [2002.11]
Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. [2002.10]
The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. [2002.05]
Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study. [2002.04]
Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy. [2002.04]
Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. [2002.04]
Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. [2002.03]
Finasteride improves male pattern hair loss in a randomized study in identical twins. [2002.01]
Effects of finasteride on vascular endothelial growth factor. [2002]
Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. [2001.12]
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. [2001.08]
A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia. [2001.07]
Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. [2001.06]
Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. [2001.05]
Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. [2001.04.15]
Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. [2001.03]
Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry. [2001.02]
Finasteride cream in hirsutism. [2001.01]
Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. [2001.01]
Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study. [2000.12]
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. [2000.11]
Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. [2000.10.01]
Finasteride increases anagen hair in men with androgenetic alopecia. [2000.10]
Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH). [2000.09]
Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. [2000.09]
A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. [2000.05]
Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes.The PLESS Study Group. [2000.05]
Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. [2000.04]
Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 . [2000.02.15]
A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. [2000.02]
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. [2000.01]
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. [2000.01]
A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. [2000]
A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. [1999.12]
Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. [1999.12]
Comparison of finasteride versus flutamide in the treatment of hirsutism. [1999.10]
|